We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Viatris Inc | NASDAQ:VTRS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.11 | -0.99% | 11.03 | 11.03 | 11.04 | 11.295 | 10.97 | 11.20 | 5,412,137 | 20:27:42 |
From May 2023 to May 2024
By Colin Kellaher
Shares of Ocuphire Pharma rose sharply in premarket trading Wednesday after the ophthalmic biopharmaceutical company and partner Viatris won U.S. Food and Drug Administration approval of their Ryzumvi eye drops.
Ocuphire and Viatris on Wednesday said the approval covers Ryzumvi for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents.
Ocuphire, based in Farmington Hills, Mich., last year inked a licensing agreement for the development and commercialization of Ryzumvi with FamyGen Life Sciences, which healthcare company Viatris acquired earlier this year.
Ocuphire and Viatris said they expect Ryzumvi to be commercially available in the U.S. in the first half of 2024.
Shares of Ocuphire, which closed Tuesday at $4.02, were recently up 9.5% to $4.40 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2023 08:43 ET (12:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Viatris Chart |
1 Month Viatris Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
